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Fibrosis can be deﬁned as an excessive accumulation of extracellular matrix (ECM) components, ultimately
leading to stiffness, scarring and devitalized tissue. MicroRNAs (miRNAs) are short, 19–25 nucleotides (nt),
non-coding RNAs involved in the post-transcriptional regulation of gene expression. Recently, miRNAs have
also emerged as powerful regulators of ﬁbrotic processes and have been termed “ﬁbromiRs”. Oxidative
stress represents a self-perpetuating mechanism in ﬁbrogenesis. MiRNAs can also inﬂuence the expression
of genes responsible for the generation of reactive oxygen species (ROS) and antioxidant defence and are
termed “redoximiRs”. Here, we review the current knowledge of mechanisms by which “redoximiRs”
regulate ﬁbrogenesis. This new set of miRNAs may be called “redoxiﬁbromiRs”.
& 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Fibrosis
Fibrosis is the ﬁnal common pathological feature of most
chronic inﬂammatory diseases. In some diseases, such as idio-
pathic pulmonary ﬁbrosis (IPF), liver cirrhosis, cardiovascular ﬁ-
brosis, systemic sclerosis and nephrosclerosis, extensive tissue
remodeling and ﬁbrosis can ultimately lead to permanent scarring
organ failure and death [1]. Fibrosis results when a normal
wound-healing response persists or becomes dysregulated,
usually in response to a severe or repetitive injury [2]. Regardless
of their distinct etiology and clinical features, chronic ﬁbrotic
disorders share the portfolio of growth factors, proteolytic en-
zymes, angiogenic factors and ﬁbrogenic cytokines that stimulate
the excessive production, deposition and contraction of ECM
components, such as hyaluronic acid, ﬁbronectin (FN), proteogly-
cans and interstitial collagens that progressively remodel and da-
mage the normal tissue architecture [3]. Transforming growth
factor-β (TGF-β) is considered to be the most potent and ubiqui-
tous pro-ﬁbrogenic cytokine [4,5]. TGF-β and local mechanical
forces, produced by inﬁltrated macrophages or resident cells, to-
gether with the ectodomain A (ED-A) sequence of FN stimulate the
activation of alpha-smooth muscle actin (α-SMA)-expressing and
ECM-producing myoﬁbroblasts, which are the key mediators of
ﬁbrotic tissue remodeling and ECM assembly [6,7]. The persistent
activation of myoﬁbroblasts leads to an excessive accumulation of
ECM components that progressively distorts normal tissueB.V. This is an open access article u
Fernández),architecture [2]. The origin of myoﬁbroblasts has been a con-
troversial subject in recent years because they differentiate from
various precursor cells that differ according to the nature of the
insult and the affected organ [8]. Thus, although activation of local
tissue ﬁbroblasts is thought to be the primary instigator of ECM
production following injury in many organs [8,9], epithelial and
endothelial cells [10–13], hepatic stellate cells [14,15], pericytes
[16], smooth muscle cells [17,18] and bone marrow-derived cells
[19–21] have been shown to differentiate into pro-ﬁbrotic myoﬁ-
broblasts during ﬁbrosis development. Whilst myoﬁbroblasts are
the primary drivers of ﬁbrosis, it is becoming increasingly clear
that various monocyte-derived cell populations can control the
ﬁbrotic process by exerting direct effects on matrix remodeling
and regulating activated myoﬁbroblasts [22].
Although it is well established that TGF-β and myoﬁbroblasts
play central roles in the development of ﬁbrosis, no effective
therapy is yet available to revert the evolution of this group of
severe connective tissue disorders.2. Oxidative stress and ﬁbrosis
Oxidative stress as a concept in redox biology and medicine
was formally deﬁned in 1985 by Helmut Sies [23] and it is cur-
rently known as an unbalance between the generation of ROS or
reactive nitrogen species (RNS) and the capacity of cells and tis-
sues to detoxify or scavenge them [24]. Mitochondria electron-
transport chain (ETC), membrane-bound NADPH oxidases (NOXs)
and endoplasmic reticulum (ER) are the three major intracellular
sources of ROS [25]. ROS-derived NOXs are particularly interestingnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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(GSH) is considered the most abundant molecule among en-
dogenous anti-oxidants [26]. GSH contributes to detoxify deleter-
ious metabolites maintaining redox homeostasis by preserving
redox potential and facilitating redox signaling [26]. The nuclear
factor-erythroid 2 related factor 2 (Nrf2) pathway is the major
regulator of cyto-protective responses to oxidative stress by reg-
ulating the expression of several enzymes involved in the anti-
oxidant response such as NOX:quinoneoxidoreductase1 (NQO1),
glutathione S-transferase (GSTs), cysteine–glutamate exchange
transporter and multidrug resistance associated protein [27,28].
ROS, generally through the action of its quintessential signaling
arm, hydrogen peroxide (H2O2), have a role in various signaling
cascades, such as in the response to growth factor stimulation and
control of inﬂammatory responses [29]. They participate in the
regulation of many cellular processes, including differentiation,
proliferation, growth, apoptosis, cytoskeletal regulation, migration,
and contraction [30]. ROS have crucial roles in critical physiolo-
gical processes [31], including the intracellular killing of bacteria
by neutrophil granulocytes [29], detoxiﬁcation by the liver [32],
thyroid hormone production [33] and crosslinking of ECM [34].
Despite its important role in physiological signaling, excessive
amounts of ROS cause direct cellular injury by inducing lipid and
protein peroxidation and damaging nucleic acids [35–37]. ROS
contribute to a wide range of pathologies including cancer, cardi-
ovascular diseases, neurological disorders, chronic inﬂammation
and autoimmune diseases [33]. Although many of the important
pathogenetic mechanisms that promote ﬁbrosis have been iden-
tiﬁed in the last decades, the precise molecular mechanisms in-
volved are not fully understood. There is a substantial and growing
body of evidences indicating the involvement of oxidative stress in
the development of ﬁbrosis in multiple organs.
2.1. Oxidative stress in pulmonary ﬁbrosis
Pulmonary ﬁbrosis is a lung disease that includes a hetero-
geneous group of lung disorders characterized by the progressive
and irreversible destruction of lung architecture caused by scar
formation that ultimately leads to death from respiratory failure
[1]. Among the ﬁbrotic lung diseases, IPF, with unknown etiology,
is the more common and severe form. Lung ﬁbrosis can also
develop after viral infections and after exposure to radiotherapy,
chemotherapeutic drugs and environmental toxins [38–41].
There are some evidences showing that ROS play an important
role in the development of pulmonary ﬁbrotic diseases. Oxidized
proteins and lipid products have been identiﬁed in exhaled air,
bronchoalveolar lavage ﬂuid and lung tissues from patients with
ﬁbrotic lung diseases. Importantly, increased ROS and oxidative
stress markers are detected in patients with IPF [42,43] and levels
of ROS negatively correlate with pulmonary function in IPF and
may predict disease severity [44]. An increase in oxidative DNA
damage has been also detected in patients with silicosis and as-
bestosis [45]. The mouse model of bleomycin-induced pulmonary
ﬁbrosis, the most commonly used experimental model, is asso-
ciated with a marked increase in ROS levels and in oxidized
proteins, DNA and lipids [46]. In this experimental model the
treatment with anti-oxidants attenuates ﬁbrosis [47–49], sug-
gesting a possible key role of oxidative stress in the development
of this pathology. TGF-β isoforms are secreted in an inactive, la-
tent form bound to a latency association protein (LAP). It has
been proposed that ROS can increase the TGF-β-induced ﬁbrosis
by activating latent TGF-β in asbestos-induced ﬁbrosis [50] and
by increasing the gene expression and secretion of TGF-β in many
cell types including alveolar epithelial cells (AECs) and macro-
phages [51]. ROS can also trigger the TGF-β1-induced ephitelial-
to-mesenchymal transition (EMT), a process that results in a lossof epithelial markers and an acquisition of a mesenchymal phe-
notype in many ﬁbrotic diseases, including IPF [52–54]. During
EMT, epithelial cells lose their cell to cell junctions and the apical-
basal polarity. EMT also enables cells to acquire invasive prop-
erties, thus degrading ECM and synthesizing new ECM compo-
nents [55]. Several recent studies indicate that ROS production by
NOXs plays a central role in the pathogenesis of pulmonary ﬁ-
brosis and inﬂammation [47,56–59]. A recent study has found
that TGF-β1 regulated the expression of NOX4, one of the major
cellular ROS sources, thus generating oxidative stress [59]. Im-
portantly, these NOX4-produced ROS are required for TGF-β1-
induced myoﬁbroblast differentiation, ECM production and con-
tractility and genetic knock-down or pharmacologic inhibition of
NOX4 prevented bleomycin-induced lung ﬁbrosis in mice [59].
Moreover, NOX4 is up-regulated in lungs of mice treated with
bleomycin and in patients with IPF [59], further highlighting the
active role of ROS in the establishment and progression of pul-
monary ﬁbrosis. NOX4 is strongly expressed in the hyperplastic
alveolar epithelium of patients with IPF, particularly in type
2 AECs. Death of AECs in pulmonary ﬁbrosis is thought to be
mediated, at least in part, by TGF-β1 and it constitutes a key
initiating and perpetuating event in pulmonary ﬁbrosis [60,61].
Studies in a NOX4 knock-down mouse support that NOX4-de-
pendent ROS are critical for the induction of AECs death by
apoptosis and the subsequent development of lung ﬁbrosis, thus
conﬁrming an important role of NOX4 induction in the patho-
genesis of tissue ﬁbrosis [60].
2.2. Oxidative stress in kidney ﬁbrosis
Renal ﬁbrosis, characterized by glomerulosclerosis and tubu-
lointerstitial ﬁbrosis, is the ﬁnal common manifestation of a wide
variety of chronic kidney diseases (CKD) [62]. The excessive and
progressive accumulation of ECM in the kidney promotes a gradual
destruction of renal tubules and functional nephrons. Oxidative
stress plays a central role in the pathogenesis of diverse chronic
inﬂammatory disorders including CKD. Patients with CKD have
markedly increased levels of oxidative stress, including increases
in lipid peroxidation, oxidation proteins products and changes in
GSH content [63–66]. The increased oxidative stress and in-
ﬂammation likely contribute to the high rates of morbidity and
mortality in this patient population [67]. Angiotensin II (Ang II),
the key contributor to the progression of renal diseases by acti-
vating pro-inﬂammatory and matrix synthesis pathways, induces
the generation of ROS by NOXs [68]. Other studies have shown a
close relationship between ROS production by NOXs and the de-
velopment of renal ﬁbrosis. For example, the production of FN in
mesangial cells induced by Ang II involves the reaction of NOX4-
derived superoxide ( ·−O2 ) with endothelial nitric oxidase synthase
(eNOS)-derived nitric oxide (NO) resulting in ONOO production
and uncoupling of eNOS, further promoting ·−O2 generation [69].
During hyperglycemia, NOX4 promotes podocyte apoptosis, an
event that signiﬁcantly contributes to the development of CKD
[70]. Although the origin of myoﬁbroblasts in the particular case of
the kidney is strongly debated [71], the role of oxidative stress has
been reported as a contributing factor in every cell type [72–79]. In
the context of renal disease, inhibition of NOX4 expression in
kidney ﬁbroblasts signiﬁcantly reduces α-SMA and ECM produc-
tion [73,80], thus conﬁrming the role of the NOX4-mediated redox
unbalance in the pro-ﬁbrotic transformation of renal ﬁbroblasts.
2.3. Oxidative stress in liver ﬁbrosis
Liver ﬁbrosis results from chronic damage to the liver in con-
junction with the accumulation of ECM proteins, which is a char-
acteristic of most types of chronic liver diseases [81]. The main
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hepatitis C virus (HCV) infection, alcohol abuse, and nonalcoholic
steatohepatitis (NASH). Advanced liver ﬁbrosis results in cirrhosis,
liver failure, and portal hypertension and often requires liver
transplantation [14]. Most of the chronic liver diseases, regardless
of the cause of the liver disorder, are characterized by increased
oxidative stress which induces liver injury and loss of liver func-
tion [82]. Oxidative stress has been also identiﬁed as a feature of
experimental models of ﬁbrosis and cirrhosis, bile duct ligation
(BDL) or carbon tetrachloride (CCl4) intoxication, suggesting their
possible role in liver ﬁbrosis. ROS contributes to the hepatic ﬁ-
brosis from various kinds of liver injuries, including alcohol abuse,
HCV infection, iron overload, and chronic cholestasis [83,84]. ROS
can stimulate the production of collagen, type I, alpha 1 (Col1α1)
and may act as intracellular signaling mediators of the ﬁbrogenic
action of TGF-β [85–87] in hepatic stellate cells (HSCs). Accumu-
lating evidence indicates that NOXs-mediated ROS play a critical
role in HSCs activation, a key event in the initiation and progres-
sion of liver ﬁbrogenesis due to the role of these cells in orches-
trating the ECM deposition in normal and ﬁbrotic liver. Direct
evidence for the contribution of NOX1 and NOX2 to hepatic ﬁ-
brogenesis was provided by attenuation of hepatic ﬁbrosis in ei-
ther NOX1 or NOX2-deﬁcient mice after CCl4 treatment or BDL
[88–90]. Several studies have shown that NOX4-generated ROS
participate in hepatic ﬁbrogenesis by inducing TGF-β1-mediated
HSCs activation [91] and triggering TGF-β- or death ligand-in-
duced hepatocyte apoptosis [91–93].
2.4. Oxidative stress in cardiac ﬁbrosis
Cardiac ﬁbrosis is one of the detrimental factors that con-
tributes to heart failure (HF) during increased cardiac workload
under conditions such as hypertension or aortic stenosis. Increased
accumulation of ECM within the myocardium, especially in the
interstitium and in perivascular areas has been implicated in the
progression of HF [2,12,94–96]. A large body of work indicates that
ROS generated by NOXs and their interactions with NO are espe-
cially important in redox signaling during the development of HF
[97–99]. Interstitial ﬁbrosis induced either by Ang II infusion or
chronic activation of the renin-angiotensin system was abrogated
in NOX2 knock-out mice [100–102]. It has been also shown that
NOX2-derived ROS contribute to contractile dysfunction, myo-
cardial atrophy, increased cardiomyocyte apoptosis, interstitial ﬁ-
brosis, and inﬂammatory cell inﬁltration in an in vivo model of
doxorubicin cardiotoxicity in mice [103], further conﬁrming the
possible role of NOX2 in cardiac ﬁbrogenesis. Some in vitro studies
have suggested that NOX4 is involved in the proliferation of cul-
tured human cardiac ﬁbroblasts and their transformation into
myoﬁbroblasts in response to TGF-β1 [104]. However, the re-
levance of these results remains to be established in vivo.
2.5. Oxidative stress in skin ﬁbrosis
In dermatology, ﬁbrosis is the hallmark component of many
skin diseases, including systemic sclerosis (SSc), keloids, hyper-
trophic scars, and graft-versus-host disease [105]. Fibrosis devel-
ops in the dermis, the connective tissue layer between the base-
ment membrane and the epidermis and is mainly composed by
ECM [106]. Fibrotic skin disorders can greatly impact patient
quality of life with organ dysfunction and psychological sequelae
[107–109]. Oxidative stress is thought to play a signiﬁcant role in
cellular functions involved in skin ﬁbrosis [110]. NOX-derived ROS
are involved at various levels of skin ﬁbrosis and interfere with
redox-sensitive intracellular signaling pathways, including inhibi-
tion of protein tyrosine phosphatases, activation of certain tran-
scription factors, and modulation of enzymes [111]. In the skin,NOX enzymes play a key role in excess ECM protein synthesis via
indirectly activating key protein tyrosine kinases [112] and may
interfere with ECM degradation by activating matrix metallopro-
teinases (MMPs) [113]. In scleroderma, a complex connective tis-
sue disorder characterized by the excessive deposition of ECM
proteins in the skin and internal organs [114], the source of oxi-
dative stress is attributed to ROS production by ﬁbroblasts and
activated leukocytes via NOX enzymes [115]. NOXs promote ﬁ-
broblast proliferation and differentiation into myoﬁbroblasts by
increasing α-SMA and collagen (Col) expression and induce the
expression of TGF-β1, the chemokine ligand (CCL)-2 and PDGFR
[115–121], thus highlighting the importance of NOX enzymes in
SSc.3. Redox-sensitive microRNAs
MiRNAs comprise a large family of conserved, small, non-cod-
ing RNAs of 19–25 nucleotides (nt) long that regulate gene ex-
pression at the post-transcriptional level by binding to the 3′-
untranslated region (3′-UTR), coding sequences or 5′-untranslated
region (5′-UTR) of target messenger RNAs and leading to the in-
hibition of translation or mRNA degradation [122,123]. Their dis-
covery in 1993 by the laboratories of Ambros and Ruvkun, re-
volutionized the comprehension of the post-transcriptional reg-
ulation of gene expression [124]. In humans, miRNAs are predicted
to control the activity of 30% of the genome. At present there are
more than 2500 miRNAs described. Each miRNAs is transcribed by
RNA polymerase II as a long precursor RNA, called primary miRNA
(pri-miRNA), which is then subjected to nuclear processing by the
Drosha–DGCR8’microprocessor’ complex. The resulting inter-
mediate, a harpin shape precursor miRNA (pre-miRNA) of 70 nt
in length, is exported to the cytoplasm and then further shortened
by Dicer, yielding a 22-nt mature miRNA. In the cytoplasm,
miRNAs associate with speciﬁc mRNAs within a multiprotein
complex of Argonaute proteins, known as the RNA-induced si-
lencing complex (RISC), providing sequence-speciﬁc silencing ac-
tivity [124]. Considering hundreds of miRNA genes, each with
many dozens of targets, it is expected that regulation by miRNAs
may occur in any cellular function in health or disease [124–127].
In the last years, it has been found that miRNAs are able to “ﬁne-
tune” the regulation of redox signaling, by direct interaction with
Nrf2, as mentioned above, the major transcriptional regulator of
the defence against ROS [27,28]. MiRNAs may also interact with its
co-regulators Kelch-like ECH-associated protein 1 (Keap1) and
CNC homolog 1 (Bach1) or regulate the generation of ROS. These
new subset of miRNAs that either regulate redox pathways or are
themselves regulated by the cellular redox state have been termed
“redoximiRs” [128].4. RedoximiRs regulate ﬁbrogenesis by diverse mechanisms
In the last decade, miRNAs have been shown to be regulators of
pro- and anti-ﬁbrotic processes in human diseases and this subset
of miRNAs are called “ﬁbromiRs” [129]. Aberrant expression of
“ﬁbromiRs” drives initiation and progression of the ﬁbrotic process
in response to persistent tissue injury [129]. Moreover, TGF-β
signaling through Smad proteins can regulate the transcription of
miRNAs by DNA binding or the miRNA maturation by associating
with the Drosha/DGCR8 complex [130], suggesting a possible link
between miRNAs and ﬁbrogenesis. Given the important role of
oxidative stress in organ ﬁbrosis, and the fact that miRNAs are
implicated in ﬁbrogenesis, the potential intersection between the
sets of “redoximiRs” and “ﬁbromiRs” team has gained increasing
interest. We propose that this subset of miRNAs may be termed
Fig. 1. miRNAs regulating NOX4-mediated ROS production. TGF-β-mediated in-
duction of NOX4 contributes to ROS generation and transformation on ﬁbroblasts
into myoﬁbroblasts. miRNAs inhibiting NOX4 expression abrogate this pro-ﬁbrotic
transformation.
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amples of representative members as well as describe their redox-
based mechanism of action and involvement in ﬁbrogenesis.
4.1. Regulation of ROS production and TGF-β–dependent myoﬁbro-
blast transformation
The best known example is constituted by those miRNAs reg-
ulating NOX4 expression. MiR-23b, miR-25 and miR-146a down-
regulate the expression of NOX4 [131–133] and as mentioned
earlier NOX4–dependent generation of H2O2 was required for TGF-
β–induced myoﬁbroblast differentiation, ECM production and
contractility [59] (Fig. 1). Importantly, He et al. demonstrated that
miR-146a inhibited the pro-ﬁbrotic TGF-β pathway by targeting
SMAD4 and also reduced HSCs proliferation and induced HSCs
apoptosis [134]. Other study showed that miR-146a modulated the
TGF-β–induced transformation of human dermal ﬁbroblasts also
by targeting SMAD4 [135], suggesting an anti-ﬁbrotic role of miR-
146a not only in liver but also in skin. Results from Fu et al. in-
dicated that miR-25 contributed to the regulation of NOX4 ex-
pression in diabetic nephropathy (DN) [131], one of the major
microvascular complications of diabetes and the most common
cause of end-stage renal disease [136]. Thus, miRNAs can reduce
ROS production by inhibiting NOX4 expression and modulating
the levels of these miRNAs may represent a therapeutic strategy
for the treatment of incurable diseases such as organ ﬁbrosis.
4.2. Regulation of anti-oxidant responses and EMT process
Regarding the miRNAs regulating cellular anti-oxidant defenses
[137], those monitoring the Nrf2 signaling pathway are some of
the most studied. Nrf2 signaling appears to be important for the
pathogenesis of ﬁbrosis. Several studies have demonstrated that
Nrf2-deﬁcient mice are more susceptible to chemically induced
oxidative stress than wild-type mice, particularly in the liver
[45,138].
MiR-34a has been shown to become up-regulated in the ageing
liver acting as a post-transcriptional repressor for key genes re-
lated to oxidative defense in the rat liver during the ageing process
[139]. The target genes repressed by miR-34a do not only includetwo key genes, Sirtuin 1 (Sirt1) and microsomal glutathione
S-transferase 1 (Mgst1), which have an important role in cellular
redox balance and resistance to oxidative stress in the liver
[140,141], but also their transcriptional activator factors, Sp1 and
Nrf2 [139]. MiR-34a has been demonstrated to exert a pro-ﬁbrotic
role in a dimethylnitrosamine (DMN)-induced hepatic ﬁbrosis in
rats by targeting the acyl-CoA synthetase long-chain family
member 1 (ACSL1) [142], thus suggesting the implication of miR-
NAs in the regulation of lipid/fatty acid metabolism involved in the
development of liver ﬁbrogenesis. In mice with preexisting pa-
thological cardiac remodeling and dysfunction due to myocardial
infarction (MI) or pressure overload via transverse aortic con-
striction (TAC), administration of locked nucleic acid (LNA)-based
antimiRs induced a decrease in miR-34a expression, improved
systolic function and reduced cardiac ﬁbrosis [143], providing
evidence that silencing of the entire miR-34 family can protect the
heart against pathological cardiac remodeling and improve cardiac
function. Another study demonstrated that miR-34a is induced
after acute MI and, importantly, the inhibition of miR-34a en-
hanced cardiac contractile recovery after acute MI [144]. These
results strongly indicate that the inhibition of miR-34a is a po-
tential therapeutic strategy to improve cardiac contractile function
after acute myocardial infarction. In keeping with the growing
interest on the regulation of antioxidant defenses by miRNAs, our
group has recently described one miRNA, miR-433, which targets
GSH biosynthetic enzymes in an Nrf2-independent manner, re-
sulting in decreased GSH levels and antioxidant capacity with
important implications for endothelial function as well as for
kidney and liver ﬁbrosis [145].
Of notice, Yang et al. showed an increase in miR-27a and miR-
27b expression induced by c-Myc in mouse models of liver ﬁbrosis
relating it to a reduction in both the expression of GSH synthetic
enzymes and Nrf2 [146], both major constituents of the anti-oxi-
dant cellular pathways. It has been shown that the down-regula-
tion of over-expressed miR-27a and miR-27b in culture-activated
rat HSCs induce a switch towards a more quiescent HSC phenotype
by restoring their ability to accumulate cytoplasmic lipid droplets
and decreasing HSCs proliferation [147]. The retinoid X receptor
alpha (RXRα) was conﬁrmed to be the target of both miRNAs [147],
highlighting the importance of regulating fatty acid metabolism
and cell proliferation during HSCs activation in an attempt to
counteract hepatic ﬁbrosis.
Members of the miR-200 family are not only the object of
regulation by changes in the redox state [128] but are also are up-
regulated by oxidative stress themselves [148] (Fig. 2). Of interest,
one speciﬁc member of the miR-200 family, miR-200a, is down-
regulated in the TGF-β1-mediated activation of HSCs but during
liver ﬁbrosis progression in humans and mice it has been reported
to increase [149]. This is in line with the induction in the expres-
sion of miR-200a in oxidative stress conditions in order to target
Keap1, which negatively modulates the stability of the master
antioxidant regulator Nrf2 [150] (Fig. 2). Noteworthy, miR-200
family members have also been closely related to EMT (Fig. 2). This
process has been proposed to be an important mechanism re-
sponsible for the accumulation of interstitial myoﬁbroblasts and
Col production during kidney ﬁbrosis [151], although this concept
is currently still controversial [152,153]. Targets of miR-200a also
include pro-ﬁbrogenic factors such as TGF-β2 and β-catenin, both
EMT-related down-stream genes [154], further conﬁrming the
involvement of miR-200a in the anti-oxidant response of HSCs
during liver injury. Of interest, ROS induce the expression of miR-
200c, which in turn represses the Zinc ﬁnger E-box binding
homeobox 1 (Zeb1). This transcription factor is one of the master
EMT-inducing genes associated with the mesenchymal phenotype
and negatively modulates E-cadherin [155], whose down-regula-
tion is a hallmark of EMT. FN is another annotated target gene for
Fig. 2. Different mechanisms of action of “redoximiRs” contribute to the regulation
of the EMT process. Several miRNAs, regulating antioxidant responses and/or being
regulated by ROS, can cooperate to control the expression of different genes related
to EMT, thus having an important role in the development of ﬁbrogenesis.
Fig. 3. miR-21 as an archetypal “redoxiﬁbromiR”. TGF-β1 and ROS induce the up-
regulation of miR-21. This pro-ﬁbrotic “redoximiR” regulates key signaling path-
ways with speciﬁc relevance in the context of organ ﬁbrosis.
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ﬁbrogenesis.
The Let-7 family of miRNAs has been implicated in the patho-
genesis of ﬁbrosis in several organs such as lung, skin or kidney
[157–160]. Let-7d is transcriptionally inhibited by TGF-β and is
signiﬁcantly decreased in the alveolar epithelium in lungs from
patients with IPF [159]. Let-7d target genes include high mobility
group A2 (HMGA2) [161] (Fig. 2), which is a key factor in the TGF-
β-EMT-induced process associated to activation of the zinc ﬁnger
Snail and the basic helix–loop–helix (bHLH) Twist transcription
factors and E-cadherin suppression [162]. Let-7a is down-regu-
lated in skin tissue and ﬁbroblasts from SSc patients and nega-
tively regulates the expression of Col [158]. Moreover, over-ex-
pression of let-7a improved the skin ﬁbrosis induced by bleomycin
in mice [158]. A study comparing miRNA proﬁles of patients with
SSc and healthy control individuals identiﬁed Let-7g as involved in
SSc pathogenesis [157]. Finally, Let-7b expression was reduced in
models of both diabetic and non-diabetic renal ﬁbrosis. Over-ex-
pression of Let-7b prevented the pro-ﬁbrotic effects of TGF-β by
repressing type I TGF-β receptor (TGFBR1) in rat proximal tubular
epithelial cells [160]. Of note, some Let-7 family members have
been shown to decrease Bach1 expression, a transcriptional re-
pressor of Nrf2 [163] (Fig. 2), in a human hepatoma cell line,
thereby attenuating oxidative injury via enhancement of Nrf2-
mediated heme oxygenase-1 (HO-1) gene expression [164].Similarly, miR-155 has been reported to inhibit Bach1 expression
[128] (Fig. 2). Up-regulation of miR-155 correlated with the degree
of lung ﬁbrosis in mice and was also found to be over-expressed in
patients with IPF [159,165]. The expression of miR-155 increased
during TGF-β-induced EMT in mammary epithelial cells through
Smad4-mediated transcriptional up-regulation and facilitated loss
of cell polarity and tight junctions by targeting the Ras homolog
family member A (RhoA) [166], implicating miR-155 in EMT
(Fig. 2).
4.3. Regulation of ERK, AKT and TGF-β signaling pathways
MiR-21, one of the most extensively studied miRNAs, is also
associated with oxidative stress [167]. Inhibition of miR-21 atte-
nuated ﬁbrosis in the heart, [168,169], kidney [170], lung [171] and
skeletal muscle [172], evoking miR-21 inhibitors as a potential
anti-ﬁbrotic therapy. It has been proposed that the transcription
factor NF-κB positively regulated miR-21 expression under H2O2-
induced oxidative stress in cardiomyocytes [167] and the up-reg-
ulation of this miRNA has been suggested to lie downstream of
NOX activation [173]. Moreover, H2O2-induced ROS activity and
cardiomyocyte apoptosis were partly protected by overexpression
of miR-21 and displayed an important role in ROS-mediated car-
diomyocyte injury [167]. MiR-21 has been implicated in cardiac
ﬁbrosis development as the expression of this miRNA was en-
hanced in the failing heart [169]. By targeting sprout homolog 1
(Spry1), an extracellular regulated kinase (ERK) inhibitor, miR-21
induces an up-regulation of ERK signaling. In vivo silencing of miR-
21 was shown to reduce cardiac ERK-mitogen-activated protein
(MAP) kinase activity, to inhibit interstitial ﬁbrosis and to at-
tenuate cardiac dysfunction in a mouse pressure-overload-induced
disease model [169]. Results of another study shown that miR-21
played an important role in TGF-β-induced endothelial-to-me-
senchymal transition (EndMT), a process that contributes to ﬁ-
broblast formation in ﬁbrotic diseases of the heart [12,174], kidney
[175–177], lung [178], liver [13] and carcinoma-associated ﬁbrosis
M. Fierro-Fernández et al. / Redox Biology 7 (2016) 58–67 63[179], by targeting the protein phosphatase and tensin homologue
(PTEN) thus regulating the AKT signaling pathway [180]. Liu et al.
[171] conﬁrmed the pro-ﬁbrotic activity of miR-21 in human IPF
and in a mouse model of bleomycin-induced lung ﬁbrosis. The
expression of miR-21 is increased in experimental ﬁbrosis and
importantly in patients with IPF [171] and miR-21 up-regulation
was proportional to the severity of lung ﬁbrosis in the bleomycin
mouse model. The enhanced expression of miR-21 led to the
suppression of Smad7 expression and favoured the assembly of
Smad2/3-Smad4 heterodimers, a crucial event in the pro-ﬁbro-
genic TGF-β signaling pathway [173]. Administration of miR-21
antisense oligonucleotides attenuated bleomycin induced-lung ﬁ-
brosis [171]. Mir-21 has been reported to be increased in SSc skin
tissues and ﬁbroblasts and the regulation of Smad7 expression was
also described in this context [181]. Studies on the role of miR-21
in renal ﬁbrosis further conﬁrmed the interaction of this miRNA
with the TGF-β signaling [170]. TGF-β increased the expression of
miR-21 in tubular epithelial cells. Smad3 knock-down mice were
protected from miR-21 up-regulation and ﬁbrosis after unilateral
uretral obstruction (UUO) kidney injury, a useful and widely used
model to examine mechanisms of tubulointerstitial ﬁbrosis in vivo
[182], indicating that the TGF-β-induced up-regulation of miR-21
is mediated by Smad3 [170]. In addition to the induction of miR-21
in the mouse ﬁbrotic kidney, this miRNA was also found to be up-
regulated in human ﬁbrotic kidney samples, especially in areas
with abundant presence of myoﬁbroblasts [183]. Importantly,
serum levels of miR-21 were signiﬁcantly elevated in patients with
kidney ﬁbrosis, showing good correlation with the severity of ﬁ-
brogenesis [183], suggesting miR-21 as a potential biomarker of
kidney ﬁbrosis. It has been proposed that miR-21 is also involved
in the development of skeletal muscle ﬁbrosis by targeting PTEN
and SMAD7 [172]. Importantly, the same authors described the
increased expression of miR-21 in muscle biopsies of Duchenne
muscular dystrophy (DMD) patients, correlating with extensive
tissue ﬁbrosis [172], thus conﬁrming the role of this miRNA in
skeletal muscle disease. Targets and signaling pathways regulated
by miR-21 are summarized in Fig. 3.
4.4. Regulation of ROS production and TGF-β signaling pathway
Recently, we have described a clear example of a novelFig. 4. Targets and anti-ﬁbrotic actions of miR-9-5p. TGF-β and ROS induce miR-9-5p e
self-limit its pro-ﬁbrogenic action. miR-9-5p inhibits the transformation of ﬁbroblasts in
different organs.“redoximiR” regulating organ ﬁbrogenesis. MiR-9-5p negatively
regulates NOX4 expression, thus controlling ROS-NOX4 produc-
tion, but it is also up-regulated in the presence of H2O2. By in-
hibiting NOX4 and type II TGF-β receptor (TGFBR2) expression,
miR-9-5p abrogated the TGF-β-dependent pro-ﬁbrotic transfor-
mation of lung ﬁbroblasts, mesothelial cells (MCs) [184] and der-
mal ﬁbroblasts (unpublished data) into myoﬁbroblasts. Con-
sistently, increased miR-9-5p levels reduced the pro-ﬁbrogenic
activities of TGF-β1 by inhibiting TGF-β1-mediated signaling. In-
creased expression of miR-9-5p results in a dramatic attenuation
of bleomycin-induced lung [184] and skin ﬁbrosis (unpublished
data). On the contrary, inhibition of miR-9-5p both in vitro and
in vivo resulted in a signiﬁcant reduction of its anti-ﬁbrotic effect
[184]. Importantly, in lung specimens from patients with IPF and in
omentum-derived MCs from patients subjected to peritoneal dia-
lysis (PD) high levels of miR-9-5p were encountered. We propose
that miR-9-5p may have a protective role in the initiation and
progression of human ﬁbrosis. It is conceivable that, for homeo-
static purposes, the crucial pro-ﬁbrogenic cytokine TGF-β triggers
counteracting responses that self-limit its deleterious action, such
as miR-9-5p (Fig. 4). In addition, miR-9-5p could also represent a
biological marker and a novel therapeutic target in lung ﬁbrosis,
still largely a devastating and incurable condition.5. In summary
It has been demonstrated that oxidative stress and the anti-
oxidant defences are crucial for ﬁbrosis development and perdur-
ability. The ﬁnding that miRNAs play an important role in the pa-
thogenesis of organ ﬁbrosis (Fig. 5) and even more, the recent
discovery of the existence of miRNAs regulating and being regulated
by ROS have uncovered the potential use of miRNAs as biomarkers
in the diagnosis, prognosis and response to treatment. The novel set
of miRNAs regulating ﬁbrogenesis through redox-based mechan-
isms may be termed “redoxiﬁbromiRs”. Therapeutic approaches
based on “redoxiﬁbromiRs” modulation may represent a novel al-
ternative for many challenging human diseases, including ﬁbrosis.xpression. TGF-β1 may induce the expression of regulators, including miR-9-5p, to
to myoﬁbroblasts by targeting TGBR2 and NOX4, thus counteracting ﬁbrogenesis in
Fig. 5. Overview of miRNAs implicated in the pathogenesis of ﬁbrosis. Selected “ﬁbromiRs” inducing (green arrows) or blocking (red blunt arrows) organ ﬁbrosis are shown.
Those being part of the “redoximiRs” set of miRNAs are represented in bold, thus generating a novel set of miRNAs called “redoxiﬁbromiRs”. (For interpretation of the
references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
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